Celgene/Agios Team Up In Long-Term Cancer Metabolism Pact
This article was originally published in The Pink Sheet Daily
Agios will receive $130 million upfront, while Celgene gains the option to develop any drugs resulting from the biotech's cancer metabolism research platform for an undisclosed period of time.
You may also be interested in...
Abbott sends another financial record tumbling as it pays an all-time high $400 million upfront for preclinical AIM compounds from Reata.
With a foundation established in oncology, Celgene is targeting new areas for growth; apremilast, for psoriasis and psoriatic arthritis, is key to the effort.
Celgene is on a course to transition from a company centered mainly on the multiple myeloma blockbuster Revlimid to a diversified biotech over the next five years. That’s the strategy management laid out for investors during an R&D day in New York April 8.